🔷 Based on results from the phase 3 BRUIN CLL-321 trial, this treatment expands options for patients progressing after prior BTK inhibitor therapy, marking a key milestone in hematologic oncology.
🔗 Read more: bit.ly/ONCOnews04-M...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #Cancer
🚨 Latest #Approval Update!
🔷 Pirtobrutinib (Jaypirca) receives approval from China’s National Medical Products Administration for relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
🔷 Based on Phase 3 VERIFY data, if approved, Rusfertide could become a first-in-class therapy, offering a novel treatment approach for patients requiring improved hematocrit control.
🔗 Read more: bit.ly/ONCOnews03-M...
#ONCOnews #OncoAlert #OncEd #BiotechNews #PharmaNews #Oncology #Hematology
🚨 Latest #FDA Approval Update!
🔷 The FDA has accepted the New Drug Application (NDA) for Rusfertide, a first-in-class hepcidin mimetic and granted Priority Review, accelerating its regulatory pathway in polycythemia vera.
🔷 The LITESPARK-022 Phase 3 data suggests added benefit from combining PD-1 blockade with HIF-2α inhibition in the post-nephrectomy setting.
🔗 Read more: bit.ly/ONCOnews02-M...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch #Immunotherapy #TargetedTherapy #RenalCellCarcinoma #KidneyCancer
🚨 Latest #Phase3 Trial Update!
🔷 Adjuvant treatment with KEYTRUDA® (pembrolizumab) plus WELIREG® (belzutifan) reduced the risk of disease recurrence or death by 28% compared to KEYTRUDA® alone in certain patients with earlier-stage Renal cell carcinoma (RCC).
✅️ Strengthen your understanding of key developments in genitourinary oncology through concise, evidence-driven questions built for both practicing oncologists and trainees.
Click here to learn more about IUCS- urologycancersummit.org
👉️ Take the Genitourinary Cancers ONCO-IQ quiz in collaboration with IUCS now —https://bit.ly/GEUR_ONCO_IQ_X
✅️ This peer-reviewed ONCO-IQ quiz, developed with the International Urology Cancer Summit (IUCS), offers oncology professionals a quick, high-yield knowledge check in minutes.
🔷 This regulatory milestone underscores continued progress in targeted therapies for lung cancer and reinforces momentum in precision oncology.
🔗 Read more: bit.ly/ONCOnews27Fe...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #Healthcare #Medicine #Innovation #Science #MedicalResearch #Pharma
🚨 Latest #FDA Approval Update!
🔷 The FDA has granted accelerated approval to zongertinib for unresectable or metastatic non-squamous NSCLC, supported by Beamion LUNG-1, which showed an ORR of 76% (95% CI: 65–85) in untreated HER2-mutant disease.
🔷 The findings signal a potential new therapeutic option for patients with limited treatment choices in advanced TNBC.
🔗 Read more: bit.ly/ONCOnews27Fe...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #Healthcare #Medicine #Innovation #Science #Oncology #CancerResearch #HealthTech
🔷 In an interim analysis of the China-based Phase 3 trial, Iza-bren achieved both dual primary endpoints of progression-free survival (PFS) and overall survival (OS).
27.02.2026 12:30 — 👍 0 🔁 0 💬 1 📌 0
🚨 Latest #Phase3 Trial Update!
🔷 SystImmune and Bristol Myers Squibb highlight Phase III interim topline results show promising efficacy for izalontamab brengitecan (Iza-bren) in previously treated unresectable or metastatic triple-negative breast cancer.
🔷 These findings reinforce the value of a bone-targeted combination strategy in improving outcomes for patients with advanced, high-risk disease.
🔗 Read more: bit.ly/ONCOnews27Fe...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #Healthcare #Medicine #Innovation #Science #MedicalResearch
🚨 Latest #Phase3 Trial Update!
🔷 Bayer’s PEACE-3 trial demonstrates a significant overall survival (OS) benefit with radium-223 dichloride plus enzalutamide in patients with metastatic castration-resistant prostate cancer and bone metastases.
🔷 This approval bolsters biomarker-driven strategies in first-line metastatic colorectal cancer, giving clinicians a new evidence-based option to improve patient outcomes.
🔗 Read more: bit.ly/ONCOnews25Fe...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerCare #ColorectalCancer #mCRC #Cancer
🚨 Latest #FDA Approval Update!
🔷 The US FDA has granted full approval to Pfizer’s BRAFTOVI® in combination with cetuximab (ERBITUX®) and fluorouracil-based chemotherapy for patients with metastatic colorectal cancer harbouring a BRAF V600E mutation, based on the global Phase 3 BREAKWATER trial.
✨ Meet Kevin Bambury at ASCO #GU2026 representing ONCOassist!
Attending ASCO GU? Let’s connect.
#ASCOGU26 #Oncology #CancerCare #DigitalHealth #MedTech #ONCOassist
🔷 Findings from the randomized, double-blind study led by GETNE provide important evidence on the role of adding targeted therapy to Somatostatin analogs in progressive NET management.
🔗 Read more: bit.ly/ONCOnews23Fe...
#ONCOnews #OncoAlert #OncEd #NeuroendocrineTumors #NETs #Oncology #Cancer
🚨 Latest #Phase 3 Trial Update!
🔷 The Phase III AXINET (GETNE 1107) trial evaluated axitinib in combination with long-acting Octreotide versus placebo plus Octreotide in patients with advanced extrapancreatic neuroendocrine tumors, assessing progression-free survival (PFS) and clinical benefit.
🔷 This first all-oral, fixed-duration (14 cycles), chemo-free regimen reduced progression/death risk by 35% vs.chemoimmunotherapy in the AMPLIFY study (HR 0.65; p=0.0038)
🔗 Read more: bit.ly/ONCOnews23Fe...
#ONCOnews #OncoAlert #OncEd #FDAApproval #CLL #Leukemia #Hematology #Oncology #Cancer
🚨 Latest #FDA Approval Update!
🔷 U.S. Food and Drug Administration has approved a combination regimen of Venclexta® (venetoclax) plus Acalabrutinib for patients with previously untreated chronic lymphocytic leukemia (CLL), expanding frontline targeted treatment options.
🔷 If approved, giredestrant could offer a targeted endocrine therapy option designed to overcome resistance associated with ESR1 mutations in HR-positive disease.
🔗 Read more: bit.ly/ONCOnews23Fe...
#ONCOnews #OncoAlert #OncEd #FDAApproval #BreastCancer #BreastCancerAwareness #Oncology
🚨 Latest #FDA Approval Update!
🔷 U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for Roche’s investigational oral selective estrogen receptor degrader (SERD) giredestrant for patients with ESR1-mutated, ER-positive advanced breast cancer.
✅️ Interpret evidence from landmark trials comparing surgery, radiotherapy, and systemic therapy
✅️ Recognize post-treatment imaging findings and adaptive treatment principles in modern radiotherapy
#Oropharynx #Oncology #OncoIQ #MedicalEducation #CancerCare #OncologyTraining #Quiz
👉️ Take the Carcinoma Oropharynx ONCO-IQ quiz now - bit.ly/CAOR_ONCO_IQ_X
This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes.
✅️ Apply biomarker-driven decision-making in HPV-associated head and neck cancers
🔷 Findings support chemotherapy-first strategies as a potential radiation-sparing option, helping reduce treatment burden while maintaining efficacy in selected patients.
🔗 Read more: bit.ly/ONCOnews20Fe...
#ONCOnews #OncoAlert #OncEd #RectalCancer #ColorectalCancer #Oncology #CancerResearch
🚨 Latest #Oncology Update!
🔷 Final phase III CONVERT trial results show neoadjuvant CAPOX (Capecitabine & Oxaliplatin) chemotherapy achieved comparable oncologic outcomes to standard chemoradiation in patients with locally advanced rectal cancer and uninvolved mesorectal fascia.
🔷 The approval expands treatment access across 33 countries, offering a new immunotherapy option for patients with limited alternatives after BCG therapy.
🔗 Read more: bit.ly/ONCOnews20Fe...
#ONCOnews #OncoAlert #OncEd #BladderCancer #Oncology #CancerTreatment #Immunotherapy #CancerResearch
🚨 Latest #Oncology Update!
🔷 ImmunityBio announces that ANKTIVA® in combination with BCG (Bacillus Calmette-Guérin) has received authorization from the European Commission for BCG-unresponsive patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
